Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-nergized donor T Cells

Rosa Bacchetta1, Barbarella Lucarelli1*, Claudia Santirana1, Silvia Gregori1, Maria T. Lupo Stanghellini2, Patrick Miqueu3, Stefan Tomiuk4, Maria Hernandez-Fuentes5, Monica E. Gianolini1, Raffaella Greco2, Massimo Bernardi2, Elisabetta Zappone2, Silvano Rossini6, Uwe Janssen4, Alessandro Ambrosi7, Monica Salomoni8, Jacopo Peccatori2, Fabio Ciceri2 and Maria-Grazia Roncarolo1,9*

1 Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy  
2 Hematology and BMT Unit, San Raffaele Hospital, Milan, Italy  
3 TcLand Expression S. A., Nantes, France  
4 Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany  
5 MRC Center for Transplantation, King’s College London, London, UK  
6 Unit of Immunohaematology and Transfusion Medicine Service, San Raffaele Hospital, Milan, Italy  
7 Center for Statistics in Biomedical Sciences, San Raffaele Scientific Institute, Milan, Italy  
8 MioMed SpA, Milan, Italy  
9 Vita-Salute San Raffaele University, Milan, Italy  

*Correspondence: Maria-Grazia Roncarolo, San Raffaele Telethon Institute for Gene Therapy, Via Olgettina 58, 20132 Milan, Italy  
e-mail: m.roncarolo@hsr.it  
† Barbarella Lucarelli and Claudia Santirana have contributed equally to this work.

T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent disease recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSCT (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-10 trial). IL-10-nergized donor T cells (IL10-DLI) contained T regulatory type 1 (Tr1) cells specific for the host alloantigens, limiting donor-vs.-host-reactivity, and memory T cells able to respond to pathogens. IL-10-DLI were infused in 12 patients with the goal of improving immune reconstitution after haplo-HSCT without increasing the risk of graft-versus-host-disease (GvHD). IL10-DLI led to fast immune reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-Vβ repertoire and T-cell functions progressively normalized after IL-10-DLI. These four patients are alive, in complete disease remission and immunosuppression-free at 72 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted (IR) patients, despite persistent host-specific hypo-reactiveness of donor T cells in vivo and enrichment of cells with Tr1-specific biomarkers in vivo. Gene-expression profiles of IR patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.

Keywords: hematopoietic stem cell transplantation, haploidentical, IL-10, T regulatory type 1 cells, cell therapy, tolerance

INTRODUCTION

The long-term benefit and wide applicability of T-cell-depleted (TCD) haploidentical-HSC transplantation (haplo-HSCT), have been limited by slow immune reconstitution and high relapse rate (1–6). Infusion of unmanipulated donor lymphocyte (DLI) to improve immune reconstitution and to prevent relapse led to high incidence of severe graft-versus-host disease (GvHD) (3, 7).

During the last decade, considerable progress has been made on the use of ex vivo manipulated T cells as a new advanced therapeutics to promote graft-versus-leukemia (GvL) and immune reconstitution without GvHD after HSCT (8, 9). For example, chimeric antigen-receptor modified T cells have been successfully employed (9–12). In addition, freshly isolated or expanded CD4+CD25+ T regulatory (Treg) cells have been used as adjuvant therapy to suppress GvHD after allogeneic HSCT in patients with hematologic malignancies (13–15). These Treg cell therapies are safe, although tested in a small number of patients, but their efficacy is still controversial. In addition, many open questions remain on the best source of Treg cells to be administered, the optimal cell dose, the survival and behavior of these cells once they are in the host environment, and their mechanism of action.

Peripheral T regulatory type 1 (Tr1) cells, with alloantigen (Allo-Ag)-specific suppressor function, have been consistently associated to a state of tolerance in chimeric patients after allogeneic HSCT. In addition, several preclinical studies demonstrated...
that Tr1 cells play a major role in the induction and maintenance of transplantation tolerance (16–21). Tr1 cells are characterized by a unique cytokine production profile (IL-10+IL-4−IL-17−) (17, 21), and by the co-expression of CD49b and LAG-3 (22). Tr1 cells control immune responses by secreting high levels of IL-10, and by killing myeloid cells (17, 23). Allo-Ag-specific Tr1 cells can be induced in vitro in the presence of IL-10 (17, 24, 25). Activation of T cells by Allo-Ags in the presence of IL-10 induces Ag-specific hypo-responsiveness, identified as T-cell anergy (26, 27). These IL-10-energized T cells contain Tr1 cells, as demonstrated at single-cell level (17), but also memory T cells able to proliferate in response to nominal Ags, such as tetanus toxoid and Candida albicans, and viral Ags, such as Epstein-Barr virus (25). In a murine model of allogeneic HSCT, transfer of IL-10-energized T cells prevented GVHD (28). These findings provided the rationale for the clinical use of IL-10-energized donor T cells (IL-10-DLI) to support immune reconstitution without severe GVHD after allo-HSCT.

We developed a GMP-validated protocol to obtain IL-10-DLI, from haploidentical hematopoietic stem cell donors (25, 29). In a small proof-of-concept clinical trial (ALT-TEN trial), 12 patients who received TCD haplo-HSCT were treated with IL-10-DLI. Here, we describe the positive outcome of TCD haplo-HSCT combined with IL-10-DLI cell therapy in four patients with high-risk/advanced stage hematologic malignancies. These patients achieved full donor chimerism, immune reconstitution, and long-term persistent disease remission. Cells from all four patients expressed biomarkers consistent with tolerance and Tr1 cell enrichment. This study indicates the feasibility of cell therapy with IL-10-DLI to promote fast immune reconstitution and tolerance after haplo-HSCT.

### MATERIALS AND METHODS

#### PATIENTS AND TRANSPLANT PROCEDURES

Nineteen patients with high-risk hematopoietic malignancies, median age 39 years (range: 20–64), were enrolled from August 2000 to October 2009 in a single center, non-randomized prospective phase I–II clinical trial (ALT-TEN protocol) approved by the San Raffaele Scientific Institute’s Ethics Committee and the Italian Ministry of Health. The clinical trial was registered in the public trial database of the Italian Istituto Superiore di Sanità (registration number IS/11/6172/8309/8391). All patients signed informed consent. Enrolled patients were candidates for haplo-HSCT from family donors, since they did not have a timely, suitable HLA-matched family or unrelated donor. Full haplotype mismatching was defined as ≥2 HLA-A, HLA-B, or DRB1 antigen disparity. At the time of trial design, information from the literature and our clinical experience clearly indicated that overall probability of survival after TCD haplo-HSCT was very poor (1). Therefore, the approval for the ALT-TEN trial, as a proof-of-concept study, was given for a small cohort of patients, and the San Raffaele Scientific Institute’s Ethics Committee agreed on a single-arm study design (see Table 1 for overall patients’ characteristics, treatment, and outcome). Patients received myeloablative conditioning and standard infection prophylaxis with voriconazole, levofloxacin, or acyclovir, followed by infusion of highly purified granulocyte-colony-stimulating (G-CSF)-mobilized CD34+ donor cells, selected with the CliniMACS one-step GMP-validated procedure (CliniMACS, Miltenyi Biotec, Bergisch-Gladbach, Germany), containing approximately 10^6 CD34+ cells/kg donor-derived T cells. Time to myeloid engraftment was defined as the first of three consecutive days of neutrophil counts ≥500/µl and platelet counts ≥25000/µl. Complete chimerism was defined as ≥95% of donor cells in the bone marrow. The distribution of patients enrolled in the trial is reported in Figure 1. Two (patients 8 and 17) of the 19 patients enrolled in the proof-of-concept ALT-TEN clinical trial were not transplanted because of relapse in the pre-conditioning phase and donor screening failure, respectively, thus they were excluded from the study because they did not undergo haplo-HSCT. Transplanted patients (n = 17) received a median of 1.2 x 10^6 CD34+ cells/kg (range, 3.8–19.2), and 1 x 10^4 CD3+ T cells/kg (range, 0.4–2.6). All but two transplanted patients (patients 12 and 19, in whom primary graft failure), achieved myeloid engraftment. Median time to an absolute neutrophil count of 500/µl and to a platelet count ≥25000/µl was 15 days (range, 10–23 and 10–26, respectively; patient 2 never reached a platelet count >25000/µl). IL-10-DLI were successfully good-manufacturing-practice (GMP)-produced in 14/17 patients (patients 10, 13, and 19: level of anergy <67%). Among these 14 patients, 2 could not be treated with IL-10-DLI because of graft failure (patient 12), or because they did not meet the eligibility criterion for early autologous reconstitution (patient 15 and patient 13, who also had no anergy). Therefore, five of the transplanted patients did not receive IL-10-DLI. Among them, two died because of infections (patients 10 and 12 at day 169 and 32 post-HSCT, respectively), two had disease recurrence (patients 13 and 15), and one (patient 19) received a second transplant from the same haploidentical donor because of graft failure.

#### IL-10-ENERGIZED T-CELL PRODUCTION AND PROTOCOL OF INFUSION

PBMC were collected by leukapheresis from the donors before G-CSF mobilization, and from the patients before the conditioning regimen. Cell manipulation was performed in GMP-validated conditions and cell product manufacture was approved by the Italian Ministry of Health. The method of cell production and the characterization of the cell product have been described in detail (25, 29). The donor-derived cell product was obtained after a mixed lymphocyte reaction (MLR) toward host-derived cells, in the presence of IL-10 (clinical-grade produced by Schering-Plough), for 10 days (MLR/10) (25). Host-derived stimulator cells were CD3-depleted PBMC. The cell product acquired host-specific hypo-responsiveness, called “anergy” and calculated as follows: [MLR – MLR/10 : MLR] x 100. Data obtained in preclinical studies showed that IL-10-energized cells do not change their phenotype as compared to the unmanipulated donor PBMC, do express very low activation markers such as CD25 and HLA-DR, are anergic toward the host alloAgs in proliferation and have a decreased frequency of (antigen specific) cytotoxic CD8+ T cell precursors.

Percentages of anergy (≥67%, calculated as above and based on mean values –2 SD of percentage of anergy obtained from more than 30 donor pairs during the process of development) and cell viability (≥70%) were chosen as release criteria because considered to be essential for safety and efficacy of the infused cells. Cell
<table>
<thead>
<tr>
<th>Pt No.</th>
<th>Sex/age</th>
<th>Disease (status at haplo-HSCT)</th>
<th>Myeloid engraftment</th>
<th>IR</th>
<th>aGvHD (grade)</th>
<th>GvHD treatment duration (months)</th>
<th>Outcome (cause)</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 M/21</td>
<td>HD (Advanced)</td>
<td>18/18 no no</td>
<td>–</td>
<td>Death (infection)</td>
<td>43</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 F/59</td>
<td>sAML (Advanced)</td>
<td>13/7 no no</td>
<td>–</td>
<td>Death (relapse)</td>
<td>72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 M/31</td>
<td>NHL (Advanced)</td>
<td>17/26 no no</td>
<td>–</td>
<td>Death (infection)</td>
<td>97</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 M/39</td>
<td>ALL (Advanced)</td>
<td>10/10 no no</td>
<td>–</td>
<td>Death (relapse)</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 F/36</td>
<td>AML (CR3)</td>
<td>11/11 18/24 (III)</td>
<td>11</td>
<td>Death (infection)</td>
<td>355</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 M/58</td>
<td>NHL (Advanced)</td>
<td>23/24 15/47 (II/III)</td>
<td>30</td>
<td>Alive/R</td>
<td>3017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 M/64</td>
<td>AML (PIF)</td>
<td>13/15 28/34 (II)</td>
<td>4</td>
<td>Alive/R</td>
<td>2653</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 M/20</td>
<td>HD (Advanced)</td>
<td>19/18 102/99 (II)</td>
<td>10</td>
<td>Alive/R</td>
<td>2441</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 F/22</td>
<td>AML (CR2)</td>
<td>17/14 33/74 (II)</td>
<td>1.5</td>
<td>Alive/R</td>
<td>2339</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 M/29</td>
<td>HD (Advanced)</td>
<td>12/20 no no</td>
<td>–</td>
<td>Death (infection)</td>
<td>69</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 F/25</td>
<td>HD (Advanced)</td>
<td>22/22 no no</td>
<td>–</td>
<td>Death (graft rejection)</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 M/39</td>
<td>AML (CR1)</td>
<td>17/17 no no</td>
<td>–</td>
<td>Death (graft rejection)</td>
<td>43</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pt No., patient number of enrollment. M, male; F, female. Diseases: HD, Hodgkin’s disease; sAML, secondary acute myeloid leukemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodisplastic syndrome; Haplo-HSCT, hematopoietic stem cell transplantation from haploidentical donors. As “advanced status of diseases” are considered lymphoproliferative disorders in partial remission or with progressive disease and acute leukemia not in remission. CR, complete remission (CR1 first, CR2 second, CR3 third); PIF, primary induction failure; PMN, polymorphonucleated cells; PLTs, platelets; IR, immune reconstitution; CD3$^+$ T cells $>$ 100/µl. IL-10-DLI, IL-10-anergized donor T cells. For patient 9, who received 2 IL-10-DLI, timing of immune reconstitution and acute GvHD onset is calculated from the first IL-10-DLI. aGVHD, acute graft-versus-host-disease.

IL-10-DLI, either fresh or frozen, were administered after sustained neutrophil engraftment and not before 1 month post-HSCT in order to exclude confounding overlapping events, such as acute GvHD due to contaminating donor T cells comprised within the graft and lytic effect of ATG toward the IL-10-DLI. All infusions were performed in the absence of Immunosuppression (IS). Eligibility criteria for IL-10-DLI were lack of immune reconstitution, defined by circulating CD4$^+$ T cells $\leq$ 50/µl, no signs of GvHD, and absence of relapse. The protocol was designed for administration of escalating cell doses every three patients (1$\times$10$^5$, 3 $\times$ 10$^5$ and 10$^6$, 3 $\times$ 10$^6$ CD3$^+$ T cells/kg), or of the dose not considered toxic in at least 10 patients.

The primary endpoints of the cell therapy trial were safety defined as no acute adverse reactions, no bone marrow aplasia and lack of GvHD > grade II unresponsive to treatment. Secondary endpoints were immune reconstitution, defined as peripheral CD3$^+$ T cells $>100$/µl (value based on the time of effective immune reconstitution reported in previous trials of adoptive transfer performed at our Institute) (10), number of infectious episodes and restored in vitro immunological functions.

**IMMUNOLOGICAL STUDIES**

Routine tests, required during follow-up after haplo-HSCT, were performed at the HSR diagnostic laboratories (Laboraf), and included complete hematological evaluation, immunophenotyping (CD3, CD4, CD8, CD16, CD56, and CD19), monitoring of blood or tissue CMV and Epstein-Barr viral loads. Furthermore, immunophenotype analyses for surface detection of CD25

![Image](www.frontiersin.org)
Table 2 | Immunophenotype and function of IL-10-DLI infused in patients of the ALT-TEN trial.

<table>
<thead>
<tr>
<th>Markers</th>
<th>Treated (n=12)</th>
<th>IR (n=5)</th>
<th>Non-IR (n=7)</th>
<th>mean</th>
<th>SD</th>
<th>mean</th>
<th>SD</th>
<th>mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunophenotype (% of positive cells in the lymphocyte gate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD2</td>
<td>78.6</td>
<td>12.4</td>
<td>79.4</td>
<td>4.0</td>
<td>77.9</td>
<td>17.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD3</td>
<td>74.0</td>
<td>13.2</td>
<td>76.8</td>
<td>7.3</td>
<td>71.7</td>
<td>17.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4</td>
<td>55.0</td>
<td>14.7</td>
<td>56.3</td>
<td>11.0</td>
<td>55.4</td>
<td>18.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD8</td>
<td>32.6</td>
<td>13.0</td>
<td>33.0</td>
<td>9.4</td>
<td>32.2</td>
<td>16.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD14</td>
<td>17.4</td>
<td>12.0</td>
<td>23.3</td>
<td>14.6</td>
<td>12.5</td>
<td>7.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD56</td>
<td>26.0</td>
<td>13.8</td>
<td>32.7</td>
<td>17.0</td>
<td>20.5</td>
<td>8.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD19</td>
<td>18.0</td>
<td>10.8</td>
<td>19.0</td>
<td>11.2</td>
<td>17.2</td>
<td>11.5</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stimulation</th>
<th>Treated (n=12)</th>
<th>IR (n=5)</th>
<th>Non-IR (n=7)</th>
<th>mean</th>
<th>SD</th>
<th>mean</th>
<th>SD</th>
<th>mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host-APC</td>
<td>76.8</td>
<td>7.7</td>
<td>80.4</td>
<td>9.3</td>
<td>74.1</td>
<td>5.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMA/IONO</td>
<td>81.3</td>
<td>16.2</td>
<td>88.8</td>
<td>15.6</td>
<td>76.0</td>
<td>15.6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cell composition and host antigen-specific unresponsiveness in secondary MLR, named anergy, and polyclonal response (to PMA+ionomycin, PMA/IONO) of IL-10-DLI prior to infusion. Percentages are calculated as percentage of proliferative responses of MLR/10 versus MLR cell cultures.

Mean values and standard deviations (SD) for the group of immune reconstituted (IR) and non-IR patients are reported. All cell products had vitality > 80%.

(2A3, BD Biosciences, San Diego, CA, USA), CD45RA (MI100, Biolegend, San Diego, CA, USA), CD62L (DREG 56, BD Biosciences, San Diego, CA, USA), CD24 (ML5, BD Biosciences, San Diego, CA, USA), CD38 (HIT2, BD Biosciences, San Diego, CA, USA), CD49b (AK-7, Biologics, San Diego, CA, USA), LAG-3 (FAB2319P, R&D System) and intracytoplasmic detection of FOXP3 (259D, Biologend, San Diego, CA, USA), GZ-B (GB11, Caltag MedSystems, Buckingham, UK), and phycoerythrin (PE)-labeled anti-IL-10 (JESS-19F1, BD Biosciences, San Diego, CA, USA) were performed on freshly or frozen isolated PBMC at HSR-TIGET. Human peripheral blood was obtained from healthy donors upon informed consent in accordance with local ethical committee approval (TIGET PERIBLOOD) and with the Helsinki Declaration. PBMC were isolated by centrifugation over Lymphoprep Ficoll gradient (Axis-Shield) and frozen in EUROzol® reagent (Euroclone Spa Life Sciences Division, Milan, Italy) for RNA extraction. Total RNA was reverse-transcribed using an Invitrogen-Life Technologies cDNA synthesis kit (Roche Diagnostics). Complementary DNA was amplified by PCR using couples of primers specific for each Vβ genes (32). The amplification products were then elongated and electrophorized on a capillary sequencer (Applied Biosystems – Life Technologies 3730) to separate them according to their length (33). The complementarity-determining-region-3 (CDR3) profiles or spectra types obtained were transformed into mathematical distributions. In parallel, the level of Vβ family transcripts was measured by real-time quantitative PCR and normalized by a housekeeping gene (HPRT). Each CDR3 length distribution was then multiplied by real-time quantitative PCR and normalized by a housekeeping gene (HPRT). Each CDR3 length distribution was then multiplied by real-time quantitative PCR and normalized by a housekeeping gene (HPRT). Each CDR3 length distribution was then multiplied by real-time quantitative PCR and normalized by a housekeeping gene (HPRT).

T-CELL REPertoire ANALYSIS

TCR repertoire analysis (TcLandscape) was performed by TcLand Expression (Nantes, France), following the standardized and validated methods established in RISET [reprograming the immune system for the establishment of tolerance (RISET)]. PBMC from patients’ blood, collected in EDTA tubes, were isolated by centrifugation over Lymphoprep Ficoll gradient (Axis-Shield) and frozen in EUROzol® reagent (Euroclone Spa Life Sciences Division, Milan, Italy) for RNA extraction. Total RNA was reverse-transcribed using an Invitrogen-Life Technologies cDNA synthesis kit (Roche Diagnostics). Complementary DNA was amplified by PCR using couples of primers specific for each Vβ genes. The amplification products were then elongated and electrophorized on a capillary sequencer (Applied Biosystems – Life Technologies 3730) to separate them according to their length. The complementarity-determining-region-3 (CDR3) profiles or spectra types obtained were transformed into mathematical distributions. In parallel, the level of Vβ family transcripts was measured by real-time quantitative PCR and normalized by a housekeeping gene (HPRT). Each CDR3 length distribution was then multiplied by the corresponding normalized Vβ transcript amounts and combined within the TcLandscape representation (34).

For in vitro functional assays total PBMC were plated at 10^3/well in 96-well plates in the presence of viral antigens: HSV-1 and -2 (2.5 µg/ml; Advanced Biotechnologies Inc., Columbia, USA) or CMV (lysat of infected human fibroblasts; diluted 1:30; kindly provided by Dr. Chiara Bonini, Laboratory of Experimental Hematology, HSR, Milan Italy). At day 4, cells were pulsed overnight with 1 µCi/well 3H-thymidine (Perkin Elmer, MA, USA). In parallel, cells were stimulated with coated anti-CD3 (10 µg/ml; OKT3; Orthoclone, Jansen-Cilag, Ratrnan, NJ, USA) and soluble anti-CD28 (1 µg/ml; BD Pharmingen, San Diego, CA, USA) mAbs, PHA (1 µg/ml; Roche Diagnostics GmbH, Mannheim, Germany), and IL-2 (50 U/ñ; Chiron Italia, Milan, Italy) for 3 days. After stimulation, cells were pulsed for 16 h with 1 µCi/well 3H-thymidine. For IFN-γ ELISPOT analysis, multi- Screen HTS 96-well plates (Millipore, Billerica, MA, USA) were coated with captured anti-human IFN-γ mAb (IFNγ ELISPOT KIT, ENELHIFNG, Thermo Scientific, Rockford, IL, USA) (30, 31).

For saturation, thawed PBMC from patients and healthy donors were added in triplicate wells (3 × 10^5 cells/well) and were incubated for 18 h at 37°C in 5% CO_2 in the presence of CMV infected cell lysis. Stimulation with PMA (10 ng/ml; Sigma, St Louis, MO, USA) plus Ionomycin (150 ng/ml; Sigma) was used as a positive control, and cells in medium alone were used as negative control. After washing, the second biotinylated anti-IFN-γ mAb (Thermo Scientific) was added, followed by Streptavidin–Alkaline Phosphatase conjugate (Roche) and then substrate (AEC Staining Kit, Sigma). After drying, spots were counted using an Elispot Reader (A. ELVIS GmbH, Hannover, Germany). The number of CMV-specific T cells, expressed as spot-forming cells per 1 × 10^6 PBMC, was calculated after the subtraction of negative control values.

1www.risetfp6.org
PCA allowed us to project the different time-points of each patient in a factorial space defined by axes, named components (C), which are linear combination of optimally weighted observed variables. The PAST software (Palstat: Statistics for Paleontologists and Paleobiologists. JS Whalley, PD Ryan 1995) was used for PCA and data representation.

GENE-EXPRESSION ANALYSIS

Microarray analysis was carried out by Miltenyi Biotec GmbH (Bergisch-Gladbach, Germany), according to the validated RISEt methods. The data discussed in this publication have been deposited in NCBI’s Gene-Expression Omnibus (35) (GSE21885). Peripheral vein blood was drawn directly into PAXgene blood RNA tubes (Qiagen, Crawley UK) and extracted using the PAxGene Blood RNA Kit, which includes DNase I treatment (Qiagen). The quality and integrity of RNA were determined using the Agilent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies). RNA was quantified by measuring A260 nm on an ND-1000 Spectrophotometer (Nanodrop Technologies). 0.5 µg total RNA was labeled using the Agilent Low RNA Input Linear Amp Kit (Agilent Technologies) as detailed in the “One-color microarray-based gene-expression analysis protocol” (version 5.5, part number G4140-90040). 0.6 µg Cy3-labeled fragmented cRNA was hybridized on the RISEt 1.0 microarray platform according to the “One-color microarray-based gene-expression analysis protocol” (version 5.5, part number G4140-90040). The last washing step was performed with acetonitrile for 30 s. RISEt 1.0 is a custom Agilent 8 K microarray platform according to the “One-color microarray-based gene-expression analysis protocol” (version 5.5, part number G4140-90040). The microarray dataset including patients 7, 9, and 11 generated on the RISEt 1.0 Agilent platform (GEO Series accession number GSE21885) was merged with the dataset obtained from the cohort of kidney transplant recipients studied by Indices of Tolerance (IOT) consortium (38) using the RISEt 2.0 platform (GEO Series accession number GSE14655), considering only the 4610 reporters present on both platforms. Expression profiles of the 10 most discriminatory biomarkers of tolerance identified by the IOT study were extracted from the combined quantile normalized, log2-transformed dataset. From this data, pairwise Pearson correlation coefficients comparing the medians of each IOT patient (Tol-DF, tolerant drug-free; s-CNI stably immunosuppressed by calcineurin inhibitors (CNI); s-nCNI, stable under non-CNI; s-LP, stable under low dose prednisolone; HC, healthy controls) were calculated with each separate time-point from patients 7, 9, and 11.

RESULTS

LONG-TERM SURVIVAL IN TRANSPLANTED PATIENTS TREATED WITH IL-10-DLI

In a pilot study, 12 patients affected by high-risk/advanced stage hematologic malignancies and previously treated with multiple lines of chemotherapy, were transplanted with haplo-HSCT and received IL-10-DLI after myeloid engraftment (ALT- TEN trial). IL-10-DLI were infused at a median of 35 days post-HSCT (range, 28–64), when no spontaneous immune reconstitution was detectable in the periphery. Cells were infused in the absence of pharmacological IS. IL-10-DLI cell dose was 10^5 CD3+ T cells/kg in all but one patient (patient 5), who received 3 x 10^5 CD3+ T cells/kg. Four patients (patients 6, 7, 9, and 11), who received IL-10-DLI at the dose of 10^5 CD3+ T cells/kg at a median of 40 days post-HSCT (range, 31–64), survived beyond day 100 post-HSCT and immune reconstituted (IR) at a median of 28 days post-IL-10-DLI (range, 15–102 days, Table 1). At present, these four long-term IR patients are IS-free with an optimal performance status at the median follow-up of 7.2 years (range 6.4–8.3). All four patients have a stable full donor chimerism. No disease relapse occurred in these reconstituted patients, despite the fact that two patients presented an advanced status of the disease at the time of transplant. Moderate acute GVHD was observed (grade II/III in patient 6 and grade II in patients 7, 9, and 11) starting at a median of


www.geneontology.org

This work was supported by "The German Research Foundation (DFG) within the framework of the Transregio 184 (SCHR 1699/1-3)" and by the German Ministry of Education and Research (01EM1207A).

Table 1

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Disease Status</th>
<th>Time of IL-10-DLI Infusion (days)</th>
<th>Follow-up (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>37</td>
<td>M</td>
<td>NHL</td>
<td>First</td>
<td>100</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>64</td>
<td>M</td>
<td>AML</td>
<td>First</td>
<td>50</td>
<td>6.5</td>
</tr>
<tr>
<td>3</td>
<td>52</td>
<td>F</td>
<td>MM</td>
<td>Second</td>
<td>150</td>
<td>5.2</td>
</tr>
<tr>
<td>4</td>
<td>48</td>
<td>M</td>
<td>AML</td>
<td>Second</td>
<td>60</td>
<td>8.3</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>M</td>
<td>MM</td>
<td>Second</td>
<td>100</td>
<td>7.2</td>
</tr>
<tr>
<td>6</td>
<td>55</td>
<td>F</td>
<td>MM</td>
<td>First</td>
<td>50</td>
<td>6.4</td>
</tr>
<tr>
<td>7</td>
<td>42</td>
<td>M</td>
<td>MM</td>
<td>First</td>
<td>100</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>50</td>
<td>F</td>
<td>MM</td>
<td>First</td>
<td>50</td>
<td>6.5</td>
</tr>
<tr>
<td>9</td>
<td>45</td>
<td>M</td>
<td>MM</td>
<td>Second</td>
<td>100</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>52</td>
<td>M</td>
<td>MM</td>
<td>Second</td>
<td>50</td>
<td>6.2</td>
</tr>
<tr>
<td>11</td>
<td>47</td>
<td>M</td>
<td>MM</td>
<td>Second</td>
<td>100</td>
<td>7</td>
</tr>
</tbody>
</table>

References

1. Bacchetta et al. Tr1 cell therapy after allogeneic HSCT

2. bacchetta-geneontology.org

www.frontiersin.org
60 days (range, 34–99) after IL-10-DLI. Acute GvHD completely resolved after conventional therapy administered for a relatively short period in patients 7, 9, and 11 (4, 10, and 1.5 months, respectively), whereas patient 6 required treatment for 39 months, and responded well to second-line therapy (Table 1). Overall, IL-10-DLI was efficacious in 4 out of 12 patients, possibly because these four patients were free of events for a time period that was sufficient for immune reconstitution to occur. The remaining eight patients included three patients who died for infections early post-HSCT (day 43, 69, and 97 in patients 1, 14, and 3, respectively) and four patients who died because of relapse or lack of engraftment (patient 2, 4, 16, and 18) shortly after transplant. One patient (patient 5) received a higher dose of IL-10-DLI (3 × 10^6 CD3^+ T cells/kg), which led to rapid immune reconstitution, but the patient developed severe GvHD unresponsive to treatment and died 1 year post-HSCT because of recurrent infections related to IS therapy (Figure 1; Table 1).

With the exception of the five IR patients described above, the overall survival of the patients treated with TCD haplo-HSCT and IL-10-DLI was comparable to that of patients receiving TCD haplo–HSCT without DLI. This negative outcome is due to the lack of immune reconstitution (not-IR) and is in line with that reported in high-risk patients treated with TCD haplo-HSCT without a complementary T-cell adoptive immunotherapy (“naked”) (1–3). None of the patients who failed to achieve immune reconstitution developed signs of GvHD.

IL-10-DLI cellular products received by the IR or not-IR patients were comparable in terms of cell composition (proportion of T, B, and NK-cells). Although not statistically different, the percentages of CD14^+ and CD56^+ were higher in IR patients as compared to non-IR patients (23.3 ± 14.6 vs. 12.5 ± 7.4% of CD14^+ cells and 32.7 ± 17 vs. 20.5 ± 8.5% of CD56^+ cells in IR and non-IR patients, respectively). Overall vitality, degree of host-specific-unresponsiveness and ability to proliferate in response to polyclonal stimulation of IL-10-DLI cell products in both IR and non-IR patients were not statistically significant (Table 2).

IL-10-DLI PROMOTED FAST IMMUNE RECONSTITUTION AFTER TCD HAPLO-HSCT

It is well established that after TCD haplo–HSCT complete functional restoration of T cells requires 6–9 months in pediatric recipients, and at least 1 year in adults (4, 5). In the four long-term surviving IL-10-DLI treated patients (patients 6, 7, 9, and 11), immune reconstitution occurred at a median of 30 days (range, 15–102) post-IL-10-DLI. At the time of immune reconstitution, the absolute number of CD3^+ T cells was >250/µl (297, 394, 256, and 925 in patients 6, 7, 9, and 11, respectively), of CD3^+ CD4^+ T cells was >150/µl (176, 163, 157, 294 in patients 6, 7, 9, and 11, respectively) and of CD3^+ CD8^+ T cells was >100/µl (115, 231, 100, 631 in patients 6, 7, 9, and 11, respectively). Figure 2A shows the kinetics of natural killer (NK)-cell and T-cell recovery in peripheral blood. Peripheral NK cells repopulated shortly after IL-10-DLI (1–2 weeks). CD3^+ CD8^+ T cells repopulated the peripheral blood before CD3^+ CD4^+ T cells, leading to a persistent CD4/CD8 inverted ratio. The highest lymphocyte counts pre-GvHD were 1235, 1291, 500, and 1685 cells/µl in patients 6, 7, 9, and 11, respectively. CD19^+ B-cells were within normal limits (median, 98/µl; range, 72–251) at a median of 199 days (range, 150–276 days). These data show a faster peripheral lymphocytes repopulation in IL-10-DLI treated patients as compared to that reported in the literature for patients post-TCD haplo–HSCT (1).

In these latter patients, NK cell recovery occurred in 2–4 weeks, whereas T-cell immune reconstitution was delayed, with CD4^+ T cells <100 and <200/µl 10 and 16 months after transplantation, respectively, and B-cell reconstitution required up to 2 years (6). In IL-10-DLI treated IR patient, peripheral T lymphocytes had an effector-memory phenotype (CD45RA^−CD62L^−), whereas naive T cells (CD45RA^+CD62L^+) were detected 1 year post-IL-10-DLI (data not shown). At long-term follow-up, total lymphocyte counts were within normal range (2100–3200 cells/µl) (Figure 2A) with naïve/memory T cell subsets and transitional, naïve, and memory B-cell subsets all represented (Figures 2B, C).

NOMAL TCR-VBETA REPERTOIRE IN IL-10-DLI TREATED PATIENTS

The evolution of the TcLandscape demonstrated that in long-term follow-up IR patients, the TCR repertoire progressively became polyclonal and comparable to that of HC. The expression of the TCR-Vβ repertoires at different time-points during the follow-up is represented in Figure 3. Results in one representative patient (Figure 3A) show that the TCR repertoire in the IL-10-DLI cell product preinfusion was similar to that of the unmanipulated donor PBMC. We observed a flat landscape early post-HSCT, which indicates the absence of T cells. T-cell reconstitution started with oligoclonal T-cell expansion (red peaks in the landscape), corresponding to clinical signs of GvHD or infections (Figure 3A). Later on the TcLandscape gradually became polyclonal (green distributions) like the donor TcLandscape. The evolution of the TCR repertoire in the long-term follow-up patients (patients 7, 9, and 11) was also analyzed by PCA on each time-series of TcLandscapes performed (Figure 3B). PCA produces a map that summarizes the similarity of TCR-Vβ chain gene-expression considering recipient cells analyzed at all time-points, donor PBMC and IL-10-DLI TcLandscapes. It is noteworthy that donor PBMC and IL-10-DLI are close on the map indicating a similar TCR repertoire. The itinerary illustrates that the divergence between the donor T-cell repertoire and the repertoire of donor T cells post-haplo–HSCT decreases with time. The TCR of the recipient progressively resembles that of the donor, starting from a depleted T-cell landscape to a fully polyclonal T-cell repertoire.

IMMUNE FUNCTIONS ARE RESTORED IN PATIENTS WITH LONG-TERM SURVIVAL

In vitro proliferative responses to IL-2 were detectable early post-IL-10-DLI, consistent with the early reconstitution of NK cells. Proliferation in response to polyclonal stimuli [anti-CD3/CD28 monoclonal antibodies (mAb) or phytohemagglutinin (PHA)] and to viral antigens [CMV and Herpes-Simplex virus (HSV)] was detected between 6 and 12 months post-infusion, after immunosuppressive therapy withdrawal (Figure 4A). Interferon (IFN)–γ-producing CMV- and HSV-specific T cells (Figure 4B) were also detected by ELISPOT analysis, confirming the presence of viral reactive T cells in the peripheral blood of long-term IR patients. It should be noted that in historical controls in vitro T-cell function was still profoundly impaired 10 months after transplantation.
Overall, even if in a limited number of patients, immune reconstitution in IL-10-DLI treated patients was consistently faster and more efficient in comparison to historical controls, with polyclonal and Ag-specific functional responses normalized within the first year.

Consistently with what observed in vitro, in long-term IR patients (patients 6, 7, 9, and 11) bacterial and fungal infections and viral reactivations mainly occurred during pharmacological IS (Figure 2A). Overall, in the first 100 days post-HSCT, the estimated median of infectious episodes was 2.75 episodes/patient in the IL-10-DLI treated long-term IR group of patients, whereas in the groups of the untreated or IL-10-DLI treated but non-IR patients, the estimated median of infectious episodes was approximately 4 episodes/patient. Importantly, no mortality related to infections was observed in the four IL-10-DLI treated IR patients, whereas the IL-10-DLI patients who did not achieve immune reconstitution died for infections and relapse at a median of 72 days from haplo-HSCT.

IL-10-DLI IMMUNE RECONSTITUTED PATIENTS MAINTAIN HOST-AG-SPECIFIC UNRESPONSIVENESS AND DISPLAY MARKERS OF IL-10-MEDIATED TOLERANCE

Donor-derived PBMC isolated from IR patients post-IL-10-DLI did not proliferate in response to host-antigen-presenting cells (APCs), in contrast to PBMC collected pre-transplant. However, these cells displayed normal responses to third party allo-APCs in vitro (Figure 5A). These results demonstrate the host-specific unresponsiveness of donor T cells after IL-10-DLI and immune reconstitution.
It is possible that host-specific unresponsiveness is maintained by the Tr1 cells infused with the IL-10-DLI cell product or by Treg cells de novo induced during IR. To test this latter hypothesis, we investigated the presence of CD4$^+$CD25$^+$FOXP3$^+$ natural T regulatory cells (nTregs) and Tr1 cells in IR patients. Percentages of nTregs were comparable in patients and in HC (average 5.2 and 4.4% in patients and HC; respectively, not shown), whereas a low proportion of cells with the Treg-specific DNA demethylated region (TSDR) of forkhead-box-protein-3 (FOXP3) was detected in patients’ whole blood as compared to HC [average 0.49% in patients (range: 0.30–0.80%) and 1.4% in HC (range: 0.4–2.9%), in line with what previously described (39).

A significantly higher percentage of granzyme-B (GZ-B)$^+$IL-10$^+$ T cells ($P = 0.0006$) and of CD49b$^+$ Lymphocyte Activation Gene 3 (LAG-3)$^+$ T cells ($P = 0.004$) was detected in the PBMC of IL-10-DLI treated patients compared to HC (Figures 5B,C). Importantly, cells expressing these biomarkers progressively increased during follow-up. This observation is consistent with the high mRNA expression of GZ-B, and LAG-3, between 6 months and 3 years post-TCD haplo-HSCT in IL-10-DLI treated patients (not shown).

In each patient, we compared the gene-expression profile at immune reconstitution, during GvHD and after immunesuppressive therapy discontinuation to that of three HC recruited in the “IOT” RISET-EU project (IOT$^4$). Consistently with the immune-reconstitution, the overall patients’ gene-expression

---

4http://www.transplant-tolerance.org.uk/
profiles gradually approximated those of the HC, as visualized in a hierarchically clustered matrix view of gene-expression (Figure 6A) and calculated by the inter-experiment correlation coefficients (>0.9). Of note, in the IL-10-DLI treated patients the gene-expression profile of the top 10 ranked genes recently identified as biomarkers of tolerance (38, 40) progressively became super-imposable to that of kidney transplanted recipients who did not reject the organ after IS withdrawal. Conversely, the gene-expression profile of the IL-10-DLI tolerant patients was different from that of transplanted patients under IS and from that of HC (Figure 6B). Notably, unlike in HC, in tolerant IL-10-DLI treated patients and tolerant kidney transplanted recipients, B-cell-related genes were highly expressed [Figure 6B and (38, 40)].

**DISCUSSION**

Patients with high-risk/advanced stage hematologic malignancies who received TCD haplo-HSCT, not followed by any kind of adoptive immunotherapy (“naked” haplo-HSCT) or followed by unmanipulated donor T-cell infusions, showed a very high rate of mortality because of infection and relapse or because of GvHD (3, 7). In the present study, 12 patients with high-risk/advance stage hematologic malignancies treated with TCD haplo-HSCT were infused with donor T cells anergized toward the host allo-Ags by IL-10. These IL-10-DLI contained both host-specific Tr1 cells and fully competent polyclonal T cells, which could down modulate host-reactivity and mediate effector responses, respectively (25). Of these 12, 4 patients had a positive outcome after TCD haplo-HSCT combined with IL-10-DLI, showing fast...
immune reconstitution with restoration of normal T naïve and memory cell subsets, progressive increase in cells positive for the Tr1 biomarkers and a tolerance signature. These IR tolerant patients are long survivors, in good performance status and remain completely disease-free at 7.2 years follow-up (median).

Patients treated with IL-10-DLI who did not immune reconstitute displayed post-transplant courses that resemble that of “naked” transplants. It remains unclear why in these patients IL-10-DLI infusions were not sufficient to sustain immune reconstitution and to prevent infections and relapse. Pre-existing poor clinical conditions and advanced disease severity at the time of transplantation could account for the lack of positive response to IL-10-DLI treatment (3, 41).

In the 4 long-term surviving patients, the infusion of IL-10-energized T cells shortly after engraftment of the myeloid compartment, correlated with an accelerated immune reconstitution with no relapse, only moderate and transient acute GvHD and no chronic GvHD. These data strongly support the notion that IL-10-DLI contributed to the overall success of the treatment. In line with this conclusion is the observation that once infused, the IL-10-DLI expanded, as demonstrated by the increase in NK-cells, CD8+, and CD4+ T cells, and by the progressive restoration of a polyclonal TCR-Vβ repertoire. However, the infused donor-derived T cells specific for the host Ags remained unresponsive in vitro. It has to be defined whether the control of host-reactivity is mediated by Tr1 cells present in the IL-10-DLI infusion, which survived long-term in vivo, or is due to de novo generated Tr1 cells. Using a combination of novel Tr1 biomarkers, we showed a progressive expansion of GZ-B (42, 43)/IL-10 and CD49b/LAG-3 (22) expressing CD4+ T cells in the peripheral blood. Importantly, the percentages of these cells were significantly higher in the IL-10-DLI long-term surviving patients [(4, 5, 6) and 6 years after TCD haplo-HSCT for patient 6, 7, 9, and 11, respectively] compared to healthy subjects. CD49b and LAG-3 are bonafide biomarkers of Tr1 cells, which are consistently detected in tolerant patients with stable mixed chimerism after allogeneic HSCT (22). These data provide evidence of the long-term presence of Tr1 cells in fully immune competent tolerant patients 5 years after haplo-HSCT and IL-10-DLI treatment. Expansion of CD4+CD25+FOXP3+ T cells was not observed at any time in long-term IR IL-10-DLI treated patients suggesting that nTregs did not have a major role in the immune reconstitution and in vivo immune modulation (44, 45).

Importantly, after HSCT, the gene-expression profile of IL-10-DLI treated patients was super-imposable to the tolerance signature of organ-transplanted patients with tolerant outcomes after IS withdrawal. Specifically, B-cell-related genes, associated with operational tolerance in stable kidney transplanted patients IS-free (38, 40) and in renal transplant recipient treated with regulatory macrophages (46) were observed in IL-10-DLI treated patients. This finding supports the hypothesis that IL-10-DLI...
treated patients have operational tolerance and provides evidence that the tolerance signature, once established, can be consistent across different clinical settings.

Results obtained in 4 haplo-HSCT transplanted patients who survived long-term after IL-10-DLI are promising especially considering that 2 of these patients were transplanted during disease relapse. However, the overall course of the trial highlights a number of limitations. In the majority of the IL-10-DLI treated patients relapse or infections occurred prior to or in time proximity with the infusion, when immunodeficiency was still severe. Therefore, the selection of patients may not have been optimal to reveal immune modulating effects of the Tr1 cells comprised in the IL-10-DLI cell product. In addition, it is possible that IL-10-DLI should have been administered earlier after transplantation, to allow parallel myeloid engraftment and immune reconstitution with better prevention of infections and relapse. Furthermore, the Tr1 cell frequency in the cell product was rather low as demonstrated in vitro by IL-10 ELISpot analysis. At the lowest effective dose, IL-10-DLI did not cause adverse effects and only moderate and transient GvHD. However, a threefold increase in cell dose provoked GvHD grade III-IV in one patient, suggesting that the ratio between effector cells and Tr1 cells was too high.

The variability in patient’s outcome was not due to differences in the anergic state of the infused IL-10-DLI since this parameter within the Indices of Tolerance (IOT) study in patients 7, 9, and 11. Pairwise Pearson correlation coefficients comparing the medians of expression in each IOT patient group (Tol-DF: tolerant drug-free; s-CNI: stably immunosuppressed by calcineurin inhibitors (CNI); s-nCNI: stable under non-CNI; s-LP: stable under low dose prednisolone; HC: healthy controls) with the expression in each separate time-point sample from patients 7, 9, and 11 are shown. The expression of the most discriminatory IOT biomarkers in IL-10-DLI treated patients progressively became super-imposable to that in Tol-DF patients and HC. The gray bars below each graph indicate immunosuppressive treatment.
was very consistent among all treated patients. However, it cannot be excluded that certain immune genetic characteristics of some patient/donor pairs, such as the combination of HLA-Ags mismatches, rendered them additionally susceptible to post-HSCT complications. In addition, the phenotype of infused IL-10-DLI cells was similar in IR patients vs. those who did not, although the former received an IL-10-DLI infusion that contained a higher, although not significant, proportion of CD56+ and CD14+ cells. The higher proportion of CD56+ cells in the IL-10-DLI may have led to earlier and better protection against infections, and possibly prevent disease relapse, after infusion, allowing T-cell expansion. Similarly, the higher proportion of CD14+ cells may reflect a higher number of APC with tolerogenic properties that could have favor, once in vivo, Tr1 cell differentiation and tolerance. Therefore, a possible contribution of NK cells and CD14+ cells in favoring faster immune reconstitution cannot be ruled out.

Early immune reconstitution post-HSCT has also been achieved with DLI genetically engineered to express the thymidine kinase suicide-gene (TK-DLI) (10), CD8-depleted DLI (47), CD25-depleted DLI (48), and CTLA4-Ig-treated BM T cells (49, 50). The incidence of severe GvHD remained high in all but the TK-DLI clinical trial, in which GvHD was controlled by acyclovir treatment, targeting the suicide-gene. Moreover, in these trials relapse occurred in a relevant proportion of patients (10). Freshly isolated or in vitro expanded Treg cells (13–15) have been infused in allo-HSCT or haplo-HSCT recipients to prevent GvHD. In these studies a reduction, but not abrogation, of GvHD was observed compared to historical controls. In addition, it should be noted that Treg cells were detected in the peripheral blood of treated patients only shortly after infusion (14). A major difference between the Treg cell trials and the trial with IL-10-DLI is that, in the former, a pool of polyclonal non-Ag-specific cells was administered, whereas we used a cell product containing adaptive in vitro primed Ag-specific Tr1 cells. A different approach to administer Ag-specific Tr1 cells has been reported in a cell therapy trial in patients affected with Chron’s disease. In this study, in vivo treatment signature was observed (51).

Overall, the small proof-of-concept clinical trial described here demonstrates the feasibility of cell therapy with host-specific Tr1 cells and shows promising, although preliminary and uncontrolled, efficacy in 4 patients. Future phase I/II trials with larger cohorts of transplanted patients, homogeneous in terms of disease and treatment, are required to further prove the efficacy of this treatment. The present study opens the possibility of using Tr1 cells as adjuvant treatment also in organ transplantation, as planned for renal transplant recipient (The ONE study, European Union Funded Multinational Clinical Trial), and in other immune-mediated disorders, including inflammatory bowel diseases and type 1 diabetes.

**AUTHOR CONTRIBUTIONS**

Rosa Bacchetta and Maria-Grazia Roncarolo designed and coordinated the study, analysed the data and wrote the paper; Fabio Ciceri supervised the clinical study; Barbara Balestri collected and analyzed data and wrote the paper; Claudia Sarritana performed immunomonitoring; Silvia Gregori contributed to cell production, Tr1 studies and to manuscript editing; Maria T. Lupo Stanghellini, Raffaella Greco, Massimo Bernardi, Jacopo Peccatori contributed to clinical monitoring; Patrick Migueu, did TCR studies; Stefan Tomiuk and Uwe Janssen did microarray analysis; Maria Hernandez-Fuentes contributed to gene-expression analysis; Elisabetta Zappone contributed to study design and initial clinical monitoring; Alessandro Ambrosi did statistical analysis; Monica Salomoni supervised cell production.

**ACKNOWLEDGMENTS**

From 2005 until the study ended, this work was funded by the EU-grant, Reprogramming the Immune System for the Establishment of Tolerance (RISET) awarded to Maria-Grazia Roncarolo. Follow-up studies were also partially supported by Italian Cancer Association (AIRC) awarded to Maria-Grazia Roncarolo. Barbara Balestri is an MD, PhD trainee supported by University La Sapienza, Rome. Patrick Migueu, Stefan Tomiuk, Uwe Janssen, and Maria Hernandez-Fuentes were also supported by RISET, and Maria Hernandez-Fuentes is part of Indices of Tolerance EU consortium. We thank: physicians and nurses of the Hematology and BMT Units of the San Raffaele Hospital for caring for patients; Lia Parma, Gabriele Torriani, and Alessio Palini for routine immunophenotyping performed at the Cytofluorimetric Facility; Katharina Fleischhauer for her useful HLA-typing evaluation and comments; Didem Aydin for technical support. We are grateful to: Sven Olek (Epiontis) for the TSDR demethylation analysis of the patients’ samples; Marco Dieci and Maria Adele Imro (MolMed) for their competent contribution to regulatory issues and GMP production; Nathalie Draux and her team (Quality Assistance) for validation studies; and Jean Ann Gilder for professional editing. Special thanks go to: Michel Goldman, RISET Coordinator, and Lucienne Chatenoud, RISET Group Leader, for encouragement and support. We are grateful to Bruce Blazar for useful contribution to the protocol design, and to Massimo F. Martelli, Franco Aversa, and Andrea Velardi for contribution to the study and helpful scientific discussions.

**REFERENCES**


5. Cavanagh-Caillon M, Andre-Schmutz I, Dal Cortivo L, Neven B, Hacein-Bey-Abina S, Fischer A. Immune reconstitution after haematopoietic stem cell


Bacchetta et al. 

T1 cell therapy after allogeneic HSCT 

www.frontiersin.org January 2014 | Volume 5 | Article 16 | 13


**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology.

Copyright © 2014 Bacchetta, Lucarelli, Sartirana, Gregori, Lupe Stanghellini, Miqueu, Tomiuk, Hernandez-Fuentes, Gianolini, Greco, Bernardi, Zappone, Rossini, Jansen, Ambrosi, Salomoni, Peccatori, Ciceri and Roncarolo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.